Boston Scientific (NYSE:BSX) Director David Habiger Purchases 2,250 Shares

Boston Scientific Corporation (NYSE:BSX) Director David Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Boston Scientific Stock Performance

BSX opened at $57.08 on Friday. The stock has a market capitalization of $84.84 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. The company has a fifty day moving average of $62.21 and a 200 day moving average of $80.40. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $26,000. Finally, United Community Bank lifted its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Truist Financial cut their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Bank of America dropped their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $92.71.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Heavy insider buying is often seen as a vote of confidence from management and can boost investor sentiment. Article Title
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the FRACTURE trial meeting all primary safety and effectiveness endpoints. That strengthens the case for future regulatory approval and supports the company’s growth story. Article Title
• Neutral Sentiment: Baird kept an Outperform rating on BSX but trimmed its price target to $75 from $78, suggesting Wall Street still likes the name even as expectations are being adjusted. Article Title
• Negative Sentiment: Some recent commentary said Boston Scientific fell due to weak results, which may be weighing on sentiment and reminding investors that the stock has faced pressure despite longer-term growth prospects. Article Title

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.